The following adverse reactions may occur. Patients should be carefully monitored, and appropriate therapeutic measures, such as discontinuing the administration, should be taken if any abnormalities are observed.
| 0.1%-5% | <0.1% | |
| Gastrointestinal | Anorexia, nausea/vomiting and diarrhea | |
| Hypersensitivitynote) | Rash | |
| Note) The incidence of adverse reactions includes the post-marketing surveillance | ||
| Reporting of suspected adverse drug reactions |
| Please contact: |
| HI-Eisai Pharmaceutical, Inc. |
| +63 2 88875837 / +63 2 88875160 / +63 9088672236 |
| Or Report to FDA Philippines: www.fda.gov.ph |
